Hatteras Venture Partners

Hatteras Venture Partners is a venture capital firm based in Durham, North Carolina, founded in 2000. The firm specializes in investing in early-stage and emerging growth companies, primarily within the life sciences and healthcare sectors. Its investment focus includes biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related technologies that enhance human health. Hatteras Venture Partners aims to support companies located in research-driven and capital-underserved regions, particularly in the Mid Atlantic and Southeastern United States. The firm typically makes initial investments ranging from $0.5 million to $4 million, with total investments reaching between $5 million and $20 million. The team at Hatteras Venture Partners possesses extensive operational experience and a successful track record, enabling them to effectively enhance the value of their portfolio companies.

John Crumpler

General Partner

Dial Ph.D., Michael

General Partner

Robert Ingram

General Partner

Lee Jr., CPA, Kenneth B.

General Partner

Robert Morff

Venture Partner

Douglas Reed

General Partner

Ben Scruggs

Principal

Simpson Ph.D., Kseniya

Associate

Jeff Terrell

General Partner

Mark Velleca

Venture Partner

118 past transactions

Atsena Therapeutics

Series C in 2025
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

410 Medical

Series B in 2025
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

BEKHealth

Venture Round in 2025
BEKhealth specializes in clinical research software that enhances the efficiency of clinical trials and observational studies. The company utilizes an AI-powered platform for chart abstraction and patient matching, which enables organizations to gain deeper insights into their patient populations. By extracting structured and unstructured data from electronic medical records, BEKhealth's technology captures three times more trial criteria, thereby facilitating faster feasibility assessments, optimizing site selection, and identifying clinically qualified participants more effectively. This approach not only accelerates timelines but also aims to increase the number of protocol-eligible candidates significantly, leading to enhanced enrollment processes and reduced costs for clients.

Synaptrix

Series A in 2024
Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC.

HistoSonics

Series D in 2024
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Endogenex

Series C in 2024
Endogenex is a medical technology company founded in 2017 that focuses on developing an innovative endoscopic procedure to assist patients with type 2 diabetes in managing their blood glucose levels. The company has created a unique therapy that employs pulsed electric fields to promote the regeneration of the duodenal mucosa, which contributes to enhanced glycemic control. By providing this novel treatment option, Endogenex aims to improve the quality of life for individuals living with type 2 diabetes.

AtaCor Medical

Series C in 2024
AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.

iVEAcare

Series A in 2024
iVEAcare focuses on developing innovative neuromodulation therapies aimed at addressing unmet clinical needs in the treatment of chronic diseases. The company creates advanced devices and software that provide targeted electrical stimulation to specific regions of the brain or spinal cord. This technology allows medical professionals to design therapies that are not only more effective but also less invasive than conventional treatments, thereby expanding access to a broader patient population.

Veralox Therapeutics

Venture Round in 2023
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

410 Medical

Series B in 2023
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

Myeloid Therapeutics

Series A in 2023
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Ten63 Therapeutics

Series A in 2023
Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

Aer Therapeutics

Series A in 2023
Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis, and asthma.

Mercy BioAnalytics

Series A in 2023
Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.

Cardiosense

Series A in 2022
Cardiosense develops a physiological waveform AI platform aimed at creating predictive biomarkers for the detection and treatment of cardiac diseases. The company utilizes raw biosignals and advanced signal processing techniques to gain insights into cardiac functions and identify pre-symptomatic markers of cardiac conditions. By leveraging multi-sensor devices and proprietary algorithms, Cardiosense focuses on non-invasive monitoring solutions that enhance healthcare professionals' ability to analyze cardiac health data and track patient well-being. This innovative approach facilitates early detection of diseases, ultimately aiming to improve patient outcomes in cardiac care.

410 Medical

Series B in 2022
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

Boomerang Medical

Series A in 2022
Boomerang Medical is a female-led bioelectronic medical technology firm that is revolutionizing the management of autoimmune illnesses.

RapidPulse

Venture Round in 2022
RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.

Code Biotherapeutics

Series A in 2022
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Wildflower Health

Venture Round in 2022
Wildflower Health, Inc. provides smartphone-based health programs aimed at connecting healthcare payers with families in the United States. Founded in 2012 and headquartered in San Francisco, the company offers a maternity program called Due Date Plus, which engages women early in pregnancy and connects them with healthcare providers or care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health needs. The platform delivers personalized health milestones based on age and gender, integrates client resources, and offers features such as on-device messaging, appointment reminders, health risk assessments, and clinical referrals. By leveraging user-centered design and technology, Wildflower Health seeks to promote smarter healthcare decisions and improve health outcomes for families over time.

Huma.AI

Series A in 2022
Huma.AI, Inc. is a technology company based in Palo Alto, California, that focuses on developing a knowledge automation platform designed to enhance efficiency in the healthcare and pharmaceutical industries. Founded in 2016, the company addresses the challenges posed by disparate systems and the vast amounts of unstructured data that complicate decision-making. By serving as a connector between data silos, Huma.AI enables users to access insights and actionable information through natural language queries. The platform is capable of extracting valuable insights from various document formats, allowing companies, scientists, and clinicians to make informed decisions quickly and effectively. Through this innovative approach, Huma.AI aims to streamline healthcare processes and improve overall operational efficiency.

AN2 Therapeutics

Series B in 2022
AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

Tune Therapeutics

Series A in 2021
Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the epigenome, the company aims to create new pathways for treatment without making changes to the DNA sequence itself. This approach allows for the potential development of therapies for complex and widespread medical conditions, positioning Tune Therapeutics at the forefront of advancements in the field of epigenetics.

Trefoil Therapeutics

Series A in 2021
Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

GeneCentric Therapeutics

Series B in 2021
GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

GoCheck

Venture Round in 2021
GoCheck, formerly known as Gobiquity, Inc., is a technology company based in Aliso Viejo, California, that specializes in mobile health applications aimed at the early detection and prevention of eye diseases in children. The company's flagship product, GoCheck Kids, is a smartphone app designed for the screening of amblyopia risk factors, adhering to guidelines established by the American Association for Pediatric Ophthalmology and Strabismus. With a focus on affordability, GoCheck Kids reduces the cost of vision screening by over 60% by utilizing the manufacturing capabilities of smartphones. The app is FDA-registered and CE certified, and it is currently utilized by over 6,500 pediatric teams across the U.S. and Europe. By facilitating early detection, GoCheck aims to combat vision impairment, a leading disabling condition among children, which can severely impact learning and overall health outcomes.

Elligo Health Research

Series E in 2021
Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Qvella

Venture Round in 2021
Qvella Corporation is a molecular diagnostics company based in Toronto, Canada, focused on revolutionizing clinical microbiology through innovative technologies. Founded in 2009 by a group of scientists and engineers, the company aims to significantly reduce the time required to obtain results for microbiological tests. Qvella's flagship technology, known as Field Activated Sample Treatment (FAST™), employs a unique electrical lysing and sample treatment method called e-lysis™. This approach allows for the rapid and direct detection of infectious agents from unenriched biological samples, such as whole blood, without the need for extensive sample processing. By delivering actionable results in clinically relevant time frames, Qvella's technology seeks to enhance patient outcomes and improve the overall practice of medicine.

Vigil Neuro

Series B in 2021
Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

RapidPulse

Series A in 2021
RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.

Veralox Therapeutics

Series A in 2021
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Standard Bariatrics

Series B in 2021
Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.
Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

StrideBio

Series B in 2021
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

Artizan Biosciences

Series A in 2021
Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Myeloid Therapeutics

Series A in 2021
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

NoviSci

Seed Round in 2021
NoviSci improve the health and well-being of people through principled data science.

Atsena Therapeutics

Series A in 2020
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

Vigil Neuro

Series A in 2020
Vigil Neuroscience Inc. is a therapeutics company focused on microglia, the brain's immune sentinel cells, to address both rare and common neurodegenerative diseases. The company aims to restore the vigilance of microglia to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies and is also developing an orally available small molecule TREM2 agonist, VG-3927, which is positioned to enter Investigational New Drug (IND) application. Additionally, Vigil is conducting the IGNITE trial, a Phase 2 proof-of-concept study that represents the first interventional trial for patients with adult-onset leukodystrophy. By leveraging modern neuroscience and various therapeutic modalities, Vigil seeks to deliver precision therapies that enhance the lives of patients and their families while expanding its pipeline and supporting the understanding of microglia biology as a critical therapeutic target.

Qvella

Venture Round in 2020
Qvella Corporation is a molecular diagnostics company based in Toronto, Canada, focused on revolutionizing clinical microbiology through innovative technologies. Founded in 2009 by a group of scientists and engineers, the company aims to significantly reduce the time required to obtain results for microbiological tests. Qvella's flagship technology, known as Field Activated Sample Treatment (FAST™), employs a unique electrical lysing and sample treatment method called e-lysis™. This approach allows for the rapid and direct detection of infectious agents from unenriched biological samples, such as whole blood, without the need for extensive sample processing. By delivering actionable results in clinically relevant time frames, Qvella's technology seeks to enhance patient outcomes and improve the overall practice of medicine.

Altis Biosystems

Seed Round in 2020
Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries. The company has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. Their organ on a chip product produces a layer of human or animal intestinal stem and differentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening.

CVRx

Venture Round in 2020
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

Shattuck Labs

Series B in 2020
Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. The company utilizes its proprietary Agonist Redirected Checkpoint (ARC) platform, which involves dual-function fusion proteins designed to enhance immune responses against tumors. Its lead product candidate, SL-172154, is undergoing Phase 1 clinical trials for the treatment of ovarian cancer, while another candidate, SL-279252, is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials for advanced solid tumors and lymphoma. Shattuck Labs aims to address a variety of cancer types through its research in immuno-oncology, leveraging its technology to promote effective immune responses and improve patient outcomes. Founded in 2016, the company is committed to advancing the field of biologic medicine.

AtaCor Medical

Series B in 2020
AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.

Atsena Therapeutics

Series A in 2020
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases that can lead to blindness. Their clinical pipeline includes therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Atsena employs an adeno-associated virus (AAV) technology platform, including a novel spreading capsid, to specifically target these retinal disorders. The company aims to prevent vision loss caused by genetic mutations through innovative ocular gene therapy solutions. With a commitment to advancing treatments for some of the most challenging forms of inherited retinal disease, Atsena Therapeutics seeks to improve the lives of patients affected by these conditions.

410 Medical

Series A in 2019
410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

GrayBug

Series C in 2019
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Trefoil Therapeutics

Series A in 2019
Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

Artizan Biosciences

Series A in 2019
Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Elligo Health Research

Series C in 2019
Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Qvella

Venture Round in 2019
Qvella Corporation is a molecular diagnostics company based in Toronto, Canada, focused on revolutionizing clinical microbiology through innovative technologies. Founded in 2009 by a group of scientists and engineers, the company aims to significantly reduce the time required to obtain results for microbiological tests. Qvella's flagship technology, known as Field Activated Sample Treatment (FAST™), employs a unique electrical lysing and sample treatment method called e-lysis™. This approach allows for the rapid and direct detection of infectious agents from unenriched biological samples, such as whole blood, without the need for extensive sample processing. By delivering actionable results in clinically relevant time frames, Qvella's technology seeks to enhance patient outcomes and improve the overall practice of medicine.

WalletFi

Convertible Note in 2018
WalletFi is a subscription management solution tailored for financial institutions and fintech companies. It offers a white-label application that helps users manage their recurring charges effectively. By utilizing machine learning technology, WalletFi identifies subscriptions, recurring payments, and Card-on-File merchants, providing personalized insights to enhance user experience. This application equips financial institutions with detailed analytics that aim to improve customer engagement and financial wellness, ultimately delivering a measurable return on investment.

Ribometrix

Series A in 2018
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

Kymera Therapeutics

Series B in 2018
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Qpex Biopharma

Series A in 2018
Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

ORIG3N

Series B in 2018
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

StrideBio

Series A in 2018
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

Standard Bariatrics

Series A in 2018
Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in developing surgical instruments designed specifically for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products, the Standard Clamp, enables surgeons to standardize their techniques, thereby reducing variation and improving efficiency during procedures. The company’s tools are intended to be used alongside general-use endoscopic staplers with reloadable cartridges, which helps to minimize the number of cartridges required for each surgery. This innovation not only lowers costs for healthcare providers but also assists in creating consistent surgical outcomes.

Clinipace

Venture Round in 2018
Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, that offers integrated clinical research services to pharmaceutical, biotechnology, and medical device companies. Established in 2003, Clinipace operates globally with additional offices in Boulder, Colorado; Buenos Aires, Argentina; São Paulo, Brazil; and regions in Europe and Asia Pacific. The organization specializes in a wide range of therapeutic areas, including oncology, cardiology, and infectious diseases, among others. Clinipace provides a comprehensive suite of services that includes clinical monitoring, biostatistics, study feasibility, patient recruitment, regulatory affairs, and project management. By focusing on collaboration and flexibility, Clinipace aims to meet the unique needs of venture-backed and mid-tier firms while maintaining a high standard of quality in clinical research.

Elligo Health Research

Series B in 2018
Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Wildflower Health

Series C in 2018
Wildflower Health, Inc. provides smartphone-based health programs aimed at connecting healthcare payers with families in the United States. Founded in 2012 and headquartered in San Francisco, the company offers a maternity program called Due Date Plus, which engages women early in pregnancy and connects them with healthcare providers or care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health needs. The platform delivers personalized health milestones based on age and gender, integrates client resources, and offers features such as on-device messaging, appointment reminders, health risk assessments, and clinical referrals. By leveraging user-centered design and technology, Wildflower Health seeks to promote smarter healthcare decisions and improve health outcomes for families over time.

Nursegrid

Venture Round in 2018
NurseGrid, founded by nurses and technology entrepreneurs, develops integrated staffing and communication tools specifically designed for nursing departments. The company offers two primary products: NurseGrid Mobile and NurseGrid Manager. NurseGrid Mobile enables nurses and healthcare workers to effectively manage their complex schedules, connect with colleagues, and enhance their work-life balance, with over 300,000 downloads and a 5-star average rating on the App Store. NurseGrid Manager streamlines team communication, staffing, and schedule management for nursing departments, ultimately increasing staff satisfaction and productivity. This tool complements existing scheduling systems, such as Kronos and McKesson, by bridging gaps between schedule creation and timekeeping. By focusing on simplifying staffing processes, NurseGrid aims to improve employee retention and job satisfaction within healthcare facilities.

Qvella

Series B in 2017
Qvella Corporation is a molecular diagnostics company based in Toronto, Canada, focused on revolutionizing clinical microbiology through innovative technologies. Founded in 2009 by a group of scientists and engineers, the company aims to significantly reduce the time required to obtain results for microbiological tests. Qvella's flagship technology, known as Field Activated Sample Treatment (FAST™), employs a unique electrical lysing and sample treatment method called e-lysis™. This approach allows for the rapid and direct detection of infectious agents from unenriched biological samples, such as whole blood, without the need for extensive sample processing. By delivering actionable results in clinically relevant time frames, Qvella's technology seeks to enhance patient outcomes and improve the overall practice of medicine.

Ribometrix

Seed Round in 2017
Ribometrix, Inc. is a biotechnology company based in Durham, North Carolina, focused on discovering and developing small molecule drugs that target functional three-dimensional RNA structures to treat various human diseases. Established in 2014, the company utilizes advanced expertise in RNA structural analysis to identify novel small molecules that can inhibit the production of proteins associated with diseases. Ribometrix's innovative platform combines proprietary RNA structure determination techniques with cutting-edge RNA tools and artificial intelligence capabilities, allowing researchers to effectively analyze and manipulate RNA biology. The company operates scientific offices in a renovated Biolabs space in Durham, along with additional offices in Chapel Hill and Boston.

Rodin Therapeutics

Series C in 2017
Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

ORIG3N

Venture Round in 2017
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

StrideBio

Seed Round in 2017
StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

MATI Energy

Series A in 2017
MATI Energy is a producer of organic caffeinated energy drinks, established in 2012 and headquartered in Durham, North Carolina. The company focuses on providing a refreshing and energizing alternative for health-conscious consumers seeking to enhance their daily performance. MATI Energy's product line features no-spike, no-crash energy drinks that include a variety of canned carbonated mixtures. These beverages are designed to deliver an energy boost while prioritizing taste and healthy ingredients, catering to active individuals who want to achieve their natural potential without compromising their health.

NeuroTronik

Series B in 2017
NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Bivarus

Series B in 2017
Bivarus, Inc. is a North Carolina-based company that specializes in a cloud-based analytics platform aimed at enhancing the patient experience and facilitating continuous quality improvement in healthcare settings. Founded in 2010, Bivarus emerged from academic research highlighting the importance of patient experience as a key predictor of health outcomes. The platform addresses the limitations of traditional patient feedback methods, which often suffer from low response rates and delayed insights. By employing a sampling algorithm, Bivarus dynamically presents a tailored set of measures to individual patients, allowing healthcare organizations to gain real-time, actionable insights into service issues, provider performance, and quality improvement efforts. Additionally, Bivarus is recognized as a CMS-approved CAHPS® partner and offers comprehensive services for assessing employee perceptions of organizational effectiveness, culture, and safety, thereby supporting engagement across healthcare organizations.

HistoSonics

Series B in 2017
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Boragen

Series A in 2017
Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. The company specializes in developing multi-functional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide aimed at crop protection, and BN2266, a fungicide that targets mRNA processing. Additionally, the company is working on a dual-function nematicide-fungicide for root protection and endo-parasiticides designed to overcome resistance. Boragen's innovative synthetic chemistry platform focuses on creating next-generation fungicides that support sustainable farming by minimizing the risk of fungicide resistance and reducing chemical usage while ensuring efficacy and performance.

Artizan Biosciences

Venture Round in 2017
Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Trefoil Therapeutics

Series A in 2017
Trefoil Therapeutics is a biotechnology company dedicated to developing innovative treatments for endothelial cell-mediated diseases, particularly focusing on corneal conditions such as Fuchs dystrophy. Utilizing its engineered fibroblast growth factor-1 (FGF-1) technology platform, Trefoil aims to create first-in-class regenerative pharmacologic therapies to address serious ophthalmic diseases that can lead to preventable blindness. The company is currently advancing a topical eye drop formulation, TTHX1114, designed to treat ulcerative conditions affecting the cornea, which can result in corneal scarring and significant vision loss. With a management team possessing over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil is committed to improving human health through protein-engineered therapies. The company has gained recognition within the biopharmaceutical community, receiving accolades from programs such as the CONNECT Springboard business plan competition and the Southeast Biotechnology Early Company Competition.

G1 Therapeutics

Series C in 2016
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

GrayBug

Series B in 2016
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Bivarus

Series A in 2016
Bivarus, Inc. is a North Carolina-based company that specializes in a cloud-based analytics platform aimed at enhancing the patient experience and facilitating continuous quality improvement in healthcare settings. Founded in 2010, Bivarus emerged from academic research highlighting the importance of patient experience as a key predictor of health outcomes. The platform addresses the limitations of traditional patient feedback methods, which often suffer from low response rates and delayed insights. By employing a sampling algorithm, Bivarus dynamically presents a tailored set of measures to individual patients, allowing healthcare organizations to gain real-time, actionable insights into service issues, provider performance, and quality improvement efforts. Additionally, Bivarus is recognized as a CMS-approved CAHPS® partner and offers comprehensive services for assessing employee perceptions of organizational effectiveness, culture, and safety, thereby supporting engagement across healthcare organizations.

ORIG3N

Series A in 2015
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Qvella

Series A in 2015
Qvella Corporation is a molecular diagnostics company based in Toronto, Canada, focused on revolutionizing clinical microbiology through innovative technologies. Founded in 2009 by a group of scientists and engineers, the company aims to significantly reduce the time required to obtain results for microbiological tests. Qvella's flagship technology, known as Field Activated Sample Treatment (FAST™), employs a unique electrical lysing and sample treatment method called e-lysis™. This approach allows for the rapid and direct detection of infectious agents from unenriched biological samples, such as whole blood, without the need for extensive sample processing. By delivering actionable results in clinically relevant time frames, Qvella's technology seeks to enhance patient outcomes and improve the overall practice of medicine.

Medfusion

Venture Round in 2015
Medfusion is a provider of patient-to-provider communication solutions that enable healthcare providers to offer service to their patients while improving office efficiency and generating revenue. Originally established in Raleigh, North Carolina in 1996, Medfusion began providing medical website development and support to healthcare clients such as hospitals, physician groups, and insurance companies. In working with healthcare entities, Medfusion developed healthcare-specific functionality such as physician directories, eligibility software, and interactive survey-taking applications.

Wildflower Health

Series B in 2015
Wildflower Health, Inc. provides smartphone-based health programs aimed at connecting healthcare payers with families in the United States. Founded in 2012 and headquartered in San Francisco, the company offers a maternity program called Due Date Plus, which engages women early in pregnancy and connects them with healthcare providers or care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health needs. The platform delivers personalized health milestones based on age and gender, integrates client resources, and offers features such as on-device messaging, appointment reminders, health risk assessments, and clinical referrals. By leveraging user-centered design and technology, Wildflower Health seeks to promote smarter healthcare decisions and improve health outcomes for families over time.

Nusirt

Series C in 2015
NuSirt Sciences, Inc. is a biotechnology company dedicated to developing innovative treatments for metabolic diseases related to over-nutrition, such as obesity and type 2 diabetes. The company has created a unique technology platform that combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to prevent and treat chronic conditions associated with aging. Its lead product, NS-0100, merges the natural compound leucine with a low dose of metformin, which is commonly used for managing early type 2 diabetes but often causes gastrointestinal side effects that limit patient tolerance. Currently, NuSirt is conducting Phase 2 clinical trials to determine the most effective dosage of NS-0100. The company has filed eleven patent applications, with two already issued, and has successfully completed several clinical and pre-clinical studies based on its proprietary technologies. Founded in 2007 and based in Nashville, Tennessee, NuSirt Sciences continues to focus on advancing solutions for chronic diseases, particularly those related to metabolic dysfunction.

Spyryx Biosciences

Series A in 2015
Spyryx Biosciences develops a next-generation therapeutics for obstructive lung diseases. Spyryx Biosciences was formed in 2013 by our scientific founder, Dr. Robert Tarran, based on his discovery of a previously unknown mechanism that the lung uses to regulate fluid on its surface. This mechanism is dysfunctional in the lungs of CF patients due to genetic mutations and is believed to be the root cause of the progressive dehydration that leads to the unfortunate cycle of mucus accumulation, bacterial colonization, immune response and tissue scarring, loss of lung function, and often early death. Spyryx's product leverages the mechanism discovered by Dr. Tarran and has shown promising results in preclinical studies by dramatically increasing survival in an animal model of CF. Their product's action is independent of the genetic mutations that cause CF, thereby having the potential to provide disease-modifying therapy to the entire CF patient population. Dr. Tarran's laboratory has also demonstrated a connection between this fluid regulation mechanism and the dehydration seen in COPD patients, who suffer from severe, chronic bronchitis and emphysema. Spyryx is investigating the application of its product to this devastating disease as well.

Contego Medical

Series B in 2015
Contego Medical, Inc. specializes in developing embolic protection devices aimed at treating cardiovascular and endovascular diseases. The company offers a range of innovative products, including angioplasty balloons and stent delivery catheters, which integrate embolic protection technology. This portfolio includes systems such as the Paladin Carotid PTA Balloon System, the Vanguard IEP Peripheral Balloon Angioplasty System, and the Excipio SV Thrombectomy Device, all designed to enhance patient outcomes and procedural efficiency during treatments for conditions like carotid artery disease, peripheral artery disease, and deep vein thrombosis. Founded in 2005 and headquartered in Raleigh, North Carolina, Contego Medical also maintains an office in Curitiba, Brazil, reflecting its commitment to addressing the needs of healthcare professionals in cardiovascular procedures.

GrayBug

Series A in 2015
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

ORIG3N

Venture Round in 2015
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

G1 Therapeutics

Series B in 2015
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

Clinipace

Private Equity Round in 2015
Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, that offers integrated clinical research services to pharmaceutical, biotechnology, and medical device companies. Established in 2003, Clinipace operates globally with additional offices in Boulder, Colorado; Buenos Aires, Argentina; São Paulo, Brazil; and regions in Europe and Asia Pacific. The organization specializes in a wide range of therapeutic areas, including oncology, cardiology, and infectious diseases, among others. Clinipace provides a comprehensive suite of services that includes clinical monitoring, biostatistics, study feasibility, patient recruitment, regulatory affairs, and project management. By focusing on collaboration and flexibility, Clinipace aims to meet the unique needs of venture-backed and mid-tier firms while maintaining a high standard of quality in clinical research.

Viamet Pharmaceuticals

Series D in 2014
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

Clearside Biomedical

Series B in 2014
Clearside Biomedical is a biopharmaceutical company focused on developing and delivering treatments for serious eye diseases, aiming to restore and preserve vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company employs a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic agents to specific compartments of the eye, such as the retina and choroid. Among its products, XIPERE is a triamcinolone acetonide injectable suspension designed for treating macular edema linked to conditions like uveitis and diabetic macular edema. Additionally, the company's CLS-AX is being developed as an axitinib formulation for suprachoroidal injection. Clearside's innovative approach provides a non-surgical and repeatable method for administering therapies, which could significantly benefit patients with sight-threatening eye diseases.

Clinverse

Series C in 2014
Clinverse is a technology company dedicated to the financial management of clinical trials, specializing in handling payments across more than 140 currencies. Its primary product, ClinPay, is a secure online platform designed to streamline the investigator payment process, significantly enhancing clinical trial productivity. ClinPay connects sponsors with investigators, facilitating timely and accurate payments while providing transparency and comprehensive auditing records. This system not only reduces study start-up times but also simplifies compliance, making it an essential tool for the efficient management of clinical trial finances.

Jumo Health

Series B in 2014
Jumo Health is a company that creates age-appropriate and culturally sensitive educational resources for patients and caregivers throughout their medical journeys. Founded in 2009 and based in New York, the company collaborates with healthcare providers, manufacturers, and advocacy groups to deliver these resources at critical moments, such as diagnosis, treatment, or during clinical trials. Jumo Health employs various engaging formats, including comic books, animations, and virtual reality experiences, to simplify complex medical topics and ensure that patients and caregivers can easily comprehend essential information. By using familiar mediums, the company aims to enhance understanding and support individuals in navigating their healthcare experiences effectively.

Curoverse

Seed Round in 2013
Curoverse, Inc. is a Boston-based company that specializes in a cloud-based open-source platform called Arvados, which is dedicated to the storage, organization, analysis, and sharing of genomic and biomedical data. Originally incorporated as Clinical Future, Inc. in 2010, the company rebranded in December 2013. Curoverse's platform is designed to meet the specific needs of genomic data management and computation, allowing scientists and clinicians to securely access and handle patient-level genomic and health data. This capability supports initiatives in drug development and precision medicine, enabling the analysis and sharing of large biomedical datasets, including genomics and imaging. As of August 2017, Curoverse operates as a subsidiary of Veritas Genetics International Ltd.

Sideris Pharmaceuticals

Series A in 2013
Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

G1 Therapeutics

Series A in 2013
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

Clearside Biomedical

Series A in 2013
Clearside Biomedical is a biopharmaceutical company focused on developing and delivering treatments for serious eye diseases, aiming to restore and preserve vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company employs a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic agents to specific compartments of the eye, such as the retina and choroid. Among its products, XIPERE is a triamcinolone acetonide injectable suspension designed for treating macular edema linked to conditions like uveitis and diabetic macular edema. Additionally, the company's CLS-AX is being developed as an axitinib formulation for suprachoroidal injection. Clearside's innovative approach provides a non-surgical and repeatable method for administering therapies, which could significantly benefit patients with sight-threatening eye diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.